Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...